Advanced search
Start date
Betweenand

Epigenetic study of histone demethylases enzymes Fe (II) and ±-ketoglutarate dependent of the jumonji family in the context of tumoral metabolism and glutaminase activity

Grant number: 14/06512-6
Support type:Scholarships in Brazil - Doctorate (Direct)
Effective date (Start): July 01, 2014
Effective date (End): February 28, 2019
Field of knowledge:Biological Sciences - Biochemistry - Chemistry of Macromolecules
Principal researcher:Sandra Martha Gomes Dias
Grantee:Krishina Ratna Sousa de Oliveira
Home Institution: Centro Nacional de Pesquisa em Energia e Materiais (CNPEM). Ministério da Ciência, Tecnologia e Inovações (Brasil). Campinas , SP, Brazil
Associated research grant:09/10875-9 - Cellular and biochemical studies of the glutaminase enzyme and its relation with cancer, AP.JP

Abstract

Enzymes that add or remove methyl groups on lysine tails of histones are sensitive to changes in cellular metabolism, because they use metabolic as co-substrates. The histone demethylases (KDMs) containing the JmjC domain (JKDMs) uses ±- ketoglutarate (±-KG) derived from the glycolytic or glutaminolitic pathways in a hydroxylation reaction that removes methyl-lysine groups from tails of histones H3 and H4. The conversion of glutamine from ±-KG is particularly important for some types of tumor cells and confers the metabolic flux required to ensure the growth and viability of these cells. It was showed that the intracellular concentration of ±-KG varies between normal and tumor cells, which may be associated with regulation of the activity of JHDMs, the tumorigenic process and maintenance of cancer stem cells (CSCs). Triple negative breast cancer (TNBC) tumors with expression profile of mesenchymal stem-like (MSL) and claudin low shows unregulated JKDM activity, are more aggressive, resistant to therapy and less differentiated, a phenotype associated with the maintenance of CSCs populations and epithelial to mesenchymal transition. In addition, these tumors consume more glutamine and have increased expression of glutaminase C (GAC). Thus, the aim of this work is to study the importance of glutaminolysis in the production of ±-KC cofactor in breast cancer model (focusing on TNBC), as well as its relationship to the maintenance of CSCs populations, their importance for EMT and cellular behaviors associated with these processes. For this, the knockdown against glutaminase 1 (GLS1) gene and/or GAC isoform, and overexpression of wild-type GAC and K320A mutation (with enhanced catalytic activity) will be conducted in three breast cell lines, MCF-10A, a non-tumoral breast lineage, MCF-7, a luminal well differentiated non-TNBC and MDA-MB-231, a lineage TNBC with MSL expression profile similar to undifferentiated claudin low tumors. Overexpression and knockdown will be confirmed by Western blot (WB) and the level of intracellular ±-KG will be measured fluorometrically. The overall methylation status of histones will be monitored passage by passage with flow cytometry, while CSCs populations will be quantified by flow cytometry using the ALDEFLUOR system. The overall methylation profile in H3 and H4 will be determined by mass spectrometry LS-MS-MS and methylation status of gene promoters associated with cell differentiation, stem-like phenotype and EMT, including TGF-², NOTCH and WNT pathways and cluster HOX genes, previously described as regulated by JHDMs, will be determined using commercial qPCR and ChIP-qPCR arrays. The occurrence of EMT will be determined by WB and immunofluorescence with antibodies against E-cadherin, N-cadherin, Vimentin and BMI-1 proteins. Finally, if determined that the EMT and increase of CSCs populations are dependent on the availability of ±-KG produced by glutaminolysis, we will perform a sphere-formation assay (functional in vitro assay to detect stem cells), cell migration assay using scratch method and invasion assay in Boyden chamber coated with Matrigel. The enzyme glutaminase has been shown to be essential for cell proliferation, but is still unknown its relationship with cellular epigenetic status. This project proposes unravel this relationship, which will help understanding this enzyme as a target in cancer research. (AU)

News published in Agência FAPESP Newsletter about the scholarship:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DIAS, MARILIA M.; ADAMOSKI, DOUGLAS; DOS REIS, LARISSA M.; ASCENCAO, CAROLLINE F. R.; DE OLIVEIRA, KRISHINA R. S.; PASCHOALINI MAFRA, ANA CAROLINA; DA SILVA BASTOS, ALLINY CRISTINY; QUINTERO, MELISSA; CASSAGO, CAROLINA DE G.; FERREIRA, IGOR M.; FIDELIS, V, CARLOS H.; ROCCO, SILVANA A.; BAJGELMAN, MARCIO CHAIM; STINE, ZACHARY; BERINDAN-NEAGOE, IOANA; CALIN, GEORGE A.; BERTELI AMBROSIO, ANDRE LUIS; GOMES DIAS, SANDRA MARTHA. GLS2 is protumorigenic in breast cancers. Oncogene, v. 39, n. 3, p. 690-702, JAN 2020. Web of Science Citations: 0.
DOS REIS, LARISSA MENEZES; ADAMOSKI, DOUGLAS; OLIVEIRA SOUZA, RODOLPHO ORNITZ; RODRIGUES ASCENCAO, CAROLLINE FERNANDA; SOUSA DE OLIVEIRA, KRISHINA RATNA; CORREA-DA-SILVA, FELIPE; DE SA PATRONI, FABIO MALTA; DIAS, MARILIA MEIRA; CONSONNI, SILVIO ROBERTO; MENDES DE MORAES-VIEIRA, PEDRO MANOEL; SILBER, ARIEL MARIANO; GOMES DIAS, SANDRA MARTHA. Dual inhibition of glutaminase and carnitine palmitoyltransferase decreases growth and migration of glutaminase inhibition-resistant triple-negative breast cancer cells. Journal of Biological Chemistry, v. 294, n. 24, p. 9342-9357, JUN 14 2019. Web of Science Citations: 3.
QUINTERO, MELISSA; ADAMOSKI, DOUGLAS; DOS REIS, LARISSA MENEZES; RODRIGUES ASCENCAO, CAROLLINE FERNANDA; SOUSA DE OLIVEIRA, KRISHINA RATNA; GONCALVES, KALIANDRA DE ALMEIDA; DIAS, MARILIA MEIRA; CARAZZOLLE, MARCELO FALSARELLA; GOMES DIAS, SANDRA MARTHA. Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer. BMC CANCER, v. 17, NOV 7 2017. Web of Science Citations: 8.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.